Clinical Trials Logo

Clinical Trial Summary

To determine the proportion of patients suffering from acute hepatic porphyria (AHP) from different hospital departments and referred to an internist referent for a suggestive clinical picture with a first negative etiological assessment.


Clinical Trial Description

In this context, this study aims to assess the prevalence of PHA in a population of patients with a suggestive clinical picture. A better knowledge of the pathology will make it possible to better guide patients and prevent them from diagnostic wandering fraught with physical and psychological consequences. This is an observational, ambispective, transversal, multicenter study carried out in France. The goal is to recruit a cohort that will reflect current practice. 500 patients will be recruted. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04923516
Study type Observational
Source Association pour la Recherche en Medecine Interne
Contact Patrice CACOUB, MD
Phone 01 42 17 80 27
Email patrice.cacoub@aphp.fr
Status Not yet recruiting
Phase
Start date June 2021
Completion date April 2022

See also
  Status Clinical Trial Phase
Completed NCT03338816 - ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP) Phase 3
Terminated NCT03547297 - INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHP
Recruiting NCT05344599 - Evaluating the Prevalence of Acute Hepatic Porphyria in Postural Tachycardia Syndrome
Completed NCT02240784 - EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)
Recruiting NCT04883905 - ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)
Approved for marketing NCT04056481 - Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria